MIBC Treatment Landscape

Host: Mark L. Gonzalgo, MD, PhD, MBA

Guest: Jen-Jane Liu, MD, FACS

CME Available: auau.auanet.org/node/44077

ACKNOWLEDGEMENTS:

Support provided by independent educational grants from:

AstraZeneca

Johnson & Johnson

LEARNING OBJECTIVES:

At the conclusion of this activity, participants will be able to:

1. Integrate immunotherapy and targeted therapy into the multimodal management of MIBC, selecting appropriate regimens and sequencing strategies based on current guidelines, clinical trial data, and patient-specific factors.

2. Evaluate the clinical role, mechanisms of action, and evidence base for targeted therapies in MIBC, including biomarker-driven selection to support personalized treatment planning.

3. Develop and apply practical approaches for preventing, monitoring, and managing immune-related adverse events and other toxicities associated with immunotherapy and targeted therapy to optimize patient safety, adherence, and quality of life.